Characterization of pandemic influenza immune memory signature after vaccination or infection

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 3129-3136

  Bonduelle, Olivia ^a,b   Carrat, Fabrice ^a,c,d   Luyt, Charles Edouard ^a,d   Leport, Catherine ^a,b,d,e   Mosnier, Anne ^a,f   Benhabiles, Nora ^a,g   Krivine, Anne ^a,h   Rozenberg, Flore ^a,h   Yahia, Nora ^a,b   Samri, Assia ^a,b   Rousset, Dominique ^a,i,j   Van Der Werf, Sylvie ^a,j   Autran, Brigitte ^a,b,k   Combadiere, Behazine ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ PARIS DIDEROT   (France)

^f Réseau des Groupes Régionaux d'Observation de la Grippe   (France)

^g DIF   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ INSTITUT PASTEUR DE LA GUYANE   (French Guiana)

^j INSTITUT PASTEUR   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

2009 H1N1 INFLUENZA; ADAPTIVE IMMUNITY; ADULT; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; DEGRANULATION; DISEASE SEVERITY; EFFECTOR CELL; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PANDEMIC INFLUENZA; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

ADAPTIVE IMMUNITY; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FRANCE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MODELS, IMMUNOLOGICAL; PANDEMICS; PRINCIPAL COMPONENT ANALYSIS; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84903751648     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74565     Document Type: Article

References (43)

1. Dawood FS, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605-2615.
2. Webster RG, Laver WG, Air GM, Schild GC. Molecular mechanisms of variation in influenza viruses. Nature. 1982;296(5853):115-121.
3. Garten RJ, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009; 325(5937):197-201.
4. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A. 1999;96(24):14001-14006.
5. Assarsson E, et al. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol. 2008;82(24):12241-12251.
6. Greenbaum JA, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A. 2009;106(48):20365-20370.
7. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983;309(1):13-17.
8. Chowell G, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med. 2009;361(7):674-679.
9. Pelat C, et al. Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France. PLoS One. 2011;6(5):e19621.
10. Ploin D, et al. Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1) pdm2009 infections-the Fluco French cohort. J Clin Virol. 2013;58(1):114-119.
11. Zarychanski R, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ. 2010;182(3):257-264.
12. Monsalvo AC, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2011;17(2):195-199.
13. To KK, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50(6):850-859.
14. To KK, et al. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin Vaccine Immunol. 2012;19(7):1012-1018.
15. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767-777.
16. Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005;23(11):1414-1425.
17. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247-258.
18. McMichael AJ, Askonas BA. Influenza virusspecific cytotoxic T cells in man; induction and properties of the cytotoxic cell. Eur J Immunol. 1978;8(10):705-711.
19. Richter M, et al. Collagen distribution and expression of collagen-binding α1β1 (VLA-1) and α2β1 (VLA-2) integrins on CD4 and CD8 T cells during influenza infection. J Immunol. 2007;178(7):4506-4516.
20. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996;272(5258):54-60.
21. Bonduelle O, et al. Longitudinal and integrative biomodeling of effector and memory immune compartments after inactivated influenza vaccination. J Immunol. 2013;191(2):623-631.
22. Raychaudhuri S, Stuart JM, Altman RB. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput. 2000;455-466.
23. Hancock K, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.N Engl J Med. 2009;361(20):1945-1952.
24. Itoh Y, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460(7258):1021-1025.
25. Wagar LE, et al. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. PLoS One. 2011;6(11):e28063.
26. Sridhar S, et al. Cellular immune correlates of protectionagainst symptomatic pandemic influenza. Nat Med. 2013;19(10):1305-1312.
27. Wilkinson TM, et al. Preexisting influenza-specific CD4(+) T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012;18(2):274-280.
28. Marois I, Cloutier A, Garneau E, Richter MV. Initial infectious dose dictates the innate, adaptive, and memory responses to influenza in the respiratory tract. J Leukoc Biol. 2012;92(1):107-121.
29. Canini L, Carrat F. Population modeling of influenzaA/H1N1 virus kinetics and symptom dynamics. J Virol. 2011;85(6):2764-2770.
30. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4T cell-mediated protection from lethal influenza:perforin and antibody-mediated mechanisms give aone-two punch. J Immunol. 2006;177(5):2888-2898.
31. Estcourt MJ, Letourneau S, McMichael AJ, HankeT. Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur J Immunol. 2005;35(9):2532-2540.
32. Abadie V, Bonduelle O, Duffy D, Parizot C, Verrier B, Combadiere B. Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice. PLoS One. 2009;4(12):e8159.
33. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum Vaccin. 2011;7(8):811-827.
34. de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, van Lier RA. Selective accumulationof differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med. 2005;202(10):1433-1442.
35. Bernard GR, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 pt 1):818-824.
36. Luyt CE, et al. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012;142(3):583-592.
37. Kendal AP, Cate TR. Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. J Clin Microbiol. 1983;18(4):930-934.
38. Dimitrov JD, Lacroix-Desmazes S, Kaveri SV. Important parameters for evaluation of antibody avidity by immunosorbent assay. Anal Biochem. 2011; 418(1):149-151.
39. Saeed AI, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques.2003;34(2):374-378.
40. Yeung KY, Haynor DR, Ruzzo WL. Validating clustering for gene expression data. Bioinformatics. 2001; 17(4):309-318.
41. Soukas A, Cohen P, Socci ND, Friedman JM. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 2000;14(8):963-980.
42. Daffertshofer A, Lamoth CJ, Meijer OG, Beek PJ. PCA in studying coordination and variability: a tutorial. Clin Biomech (Bristol, Avon). 2004;19(4):415-428.
43. Roden JC, King BW, Trout D, Mortazavi A, Wold BJ, Hart CE. Mining gene expression data by interpreting principal components. BMC Bioinformatics. 2006;7:194.